crizanlizumab-tmca (Adakveo)
crizanlizumab-tmca is an FDA-licensed reference biologic from Novartis Pharmaceuticals Corporation. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2019
Reference approved
Reference product
Adakveo crizanlizumab-tmca
Novartis Pharmaceuticals Corporation
- Approved
- Nov 15, 2019
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for crizanlizumab-tmca, in chronological order.
Reference approval
Approval date of the reference crizanlizumab-tmca product.
6 yr 8 mo ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
in 6 mo
Frequently asked questions
Are there biosimilars approved for crizanlizumab-tmca (Adakveo)?
No 351(k) biosimilars or interchangeable biosimilars referencing crizanlizumab-tmca are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.